EMVision Validates Brain Scanner for Aeromedical Stroke Care

Aeromedical Study Confirms Device Readiness for Remote Stroke Care

EMVision Medical Devices (ASX:EMV) has cleared a significant hurdle in its quest to revolutionise stroke diagnosis in rural and remote Australia. The First Responder Brain Scanner completed a rigorous aeromedical feasibility and usability study with the Royal Flying Doctor Service (RFDS), demonstrating it can be deployed and operated effectively in challenging pre-hospital environments. This real-world validation is a crucial step toward commercialising a device designed to slash delays in stroke diagnosis where time is brain.

The study involved 17 patients transported on 15 aeromedical transfers from 12 airstrips up to 371 kilometres from Adelaide Airport. Flight nurses, who are the primary operators, rated the device highly across preparation, patient set-up, and operation domains, with over 90% positive usability responses. Patients also responded well, with 92% reporting feeling calm during scans and all indicating comfort with the scanner's use on family members. Crucially, scan data quality remained consistent despite the vibrations and motion inherent in flight conditions, matching the standards of scans conducted in controlled clinical settings.

Operational Insights and Scan Performance

The median scan time was just over five minutes, including a redundant sequence for safety, with expectations that production models will reduce this further. The study’s comprehensive logging of environmental variables such as temperature, vibration, and device motion confirmed the scanner’s robustness. This performance underpins the device’s potential to provide rapid neurodiagnostic information in the narrow therapeutic window critical for stroke interventions like thrombolysis or thrombectomy.

EMVision’s progress builds on momentum from its broader clinical programs, including the ongoing Mobile Stroke Unit study and preparations for a standard road ambulance trial, which together are accumulating real-world evidence across the stroke care continuum. These efforts complement the company’s pivotal FDA trial, which recently expanded to include acute ischaemia detection, with over 125 patients enrolled across multiple hospitals acute ischaemia detection. The company’s strong cash position, bolstered by recent milestone payments and grants, supports this clinical expansion FDA trial and pre-hospital studies.

Commercialisation and Regulatory Pathway

EMVision has received the final $400,000 milestone payment under the Australian Stroke Alliance project, funded by the Medical Research Future Fund, marking a tangible financial endorsement of its progress. The company is now advancing production equivalent commercial units designed to exceed the first-generation emu™ Brain Scanner in performance, usability, and manufacturability. These units will support further data collection, diagnostic performance evaluation, and substantial equivalence testing essential for regulatory clearance.

International interest is growing, with presentations at the European Stroke Organisation Conference and the PRESTO satellite meeting highlighting the device’s potential to transform stroke care globally. The challenge of delivering timely neuroimaging in rural and remote areas remains acute, and EMVision’s technology aims to close this gap by enabling early triage and treatment decisions during aeromedical retrievals.